News Summary

The U.S. Food and Drug Administration (FDA) has approved the first-ever oral version of Wegovy, a weight-loss drug developed by Novo Nordisk. The Wegovy pill, which contains the active ingredient semaglutide, offers an alternative to the original weekly injection version. This approval marks the first introduction of a GLP-1 pill specifically for obesity treatment. Clinical trials have shown that participants taking the highest dose of the Wegovy pill lost an average of 16.6% of their body weight over 64 weeks. The pill will be available in early January and is priced at $149 per month for the starting dose. The approval could potentially widen access to effective obesity treatment for many, as the pill form may be more convenient for some patients.